Skip to content
Search

Latest Stories

Ex-Haleon VP Bas Vorsteveld joins Kenvue

Kenvue appoints Bas Vorsteveld as area managing director for Northern Europe
Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

Bas Vorsteveld announced his departure from Haleon in October 2024, after “a journey of nearly 19 amazing years”

Bas Vorsteveld, former Haleon’s vice-president and general manager for Great Britain and Ireland (GBI), has been appointed as Kenvue's new area managing director for Northern Europe.

In his new role, he will oversee the company’s operations across the UK, Ireland, Norway, Sweden, Denmark, and Finland, managing a portfolio of iconic brands, including Nicorette, Aveeno, Johnson’s Baby, Listerine, Neutrogena, Calpol, OGX, and Imodium.


Vorsteveld has over 30 years of experience in consumer goods and healthcare.

At Haleon, he played a pivotal role in driving its GBI business following its separation from GSK, delivering significant growth and earning notable recognition, including Best Company at the UK Pharmacy Awards 2024.

He announced his departure from Haleon in October 2024, after “a journey of nearly 19 amazing years.”

Until recently, Vorsteveld was president of the board of the PAGB, spearheading the organisation’s five-year strategy focused on advancing self-care to help alleviate healthcare pressures.

He has held several roles across Europe with GSK Consumer Healthcare including VP & Head of Commercial Excellence EMEA, VP & General Manager France and French speaking Africa & Maghreb, and GM Benelux. Prior to that, he held GM roles at Novartis. He started his career at Campina.

Expressing his enthusiasm for the new role, Vorsteveld said: “Kenvue’s iconic brands speak for themselves, and I am excited by the truly holistic approach to self-care we can offer through the entire range of different categories we thrive in.

“I’m thrilled to join the Northern Europe team, and I look forward to getting out across the region to spend time with our customers and stakeholders across the industry as well as our dedicated team.”

Welcoming Bas to the leadership team, Carlton Lawson, group president, Europe, Middle East, Africa and Latin America at Kenvue, said: “With almost three decades of experience in consumer goods and healthcare, Bas brings a proven track record of delivering industry leading growth, building high performing teams and deep industry knowledge that will be invaluable as we work to further boost Kenvue’s regional performance and growth.

“I’m confident that his experience advocating for the role our industry can and should play in promoting the value of self-care will help us deliver on our clear purpose to put the power of everyday care into the hands of more consumers.”

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less